The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Adverse side‐effects to biological agents
Open accessAbstract
Biological agents‐like cytokines, monoclonal antibodies and fusion proteins are widely used in anti‐inflammatory and tumour therapy. They are highly efficient in certain diseases, but can cause a great variety of adverse side‐effects. Based on the peculiar features of biological agents a new classification of these adverse side‐effects of biological agents is proposed – related but clearly distinct from the classification of side‐effects observed with chemicals and drugs. This classification differentiates five distinct types, namely clinical reactions because of high cytokine levels (type α), hypersensitivity because of an immune reaction against the biological agent (β), immune or cytokine imbalance syndromes (γ), symptoms because of cross‐reactivity (δ) and symptoms not directly affecting the immune system (ɛ). This classification could help to better deal with the clinical features of these side‐effects, to identify possible individual and general risk factors and to direct research in this novel area of medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Functional diversity of helper T lymphocytes
Abbas, A. K., Murphy, K. M., & Sher, A. (1996) · Nature · doi:10.1038/383787a0 · Cited by 4,450
Cellular and Molecular Immunology
Abbas, A. K., Lichtman, A. H., & Pillai, S. S. (1994) · Cited by 3,583
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Cellular and Molecular Immunology
Denman, A. M. (1992) · Postgraduate Medical Journal · doi:10.1136/pgmj.68.798.305 · Cited by 2,800
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 1×
“Abrogating the suppressive function of activated CTLA4+ T cells, which have immunoregulatory properties, by anti-CTLA4 antibodies (MDX-010) may also lead to skin symptoms like an eosinophilic dermatitis similar to drug hypersensitivity (28).”
BackgroundINFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
Gómez‐Reino, J. J., Carmona, L., Valverde, V. R., Mola, E. M., & Montero, M. D. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11137 · Cited by 1,013
Delayed Drug Hypersensitivity Reactions
Pichler, W. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00012 · Cited by 735
Self-citationCutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
Peréz-Soler, R., & Saltz, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.6916 · Cited by 486
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
Kwon, H. J., Cot, T. R., Cuffe, M. S., Kramer, J. M., & Braun, M. M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-10-200305200-00008 · Cited by 455
Toll‐like receptors, endogenous ligands, and systemic autoimmune disease
Rifkin, I. R., Leadbetter, E. A., Busconi, L., Viglianti, G., & Marshak‐Rothstein, A. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00239.x · Cited by 389
Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., & Rutgeerts, P. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00701-7 · Cited by 327
Autoimmunity through Cytokine-Induced Dendritic Cell Activation
Banchereau, J., Pascual, V., & Palucka, A. K. (2004) · Immunity · doi:10.1016/s1074-7613(04)00108-6 · Cited by 293
Daclizumab to Prevent Rejection after Cardiac Transplantation
Hershberger, R. E., Starling, R. C., Eisen, H. J., Bergh, C.-H., Kormos, R. L., Love, R. B., Van Bakel, A., Gordon, R. D., Popat, R., Cockey, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032953 · Cited by 205
Anti-TNF-?-induced systemic lupus syndrome
Debandt, M., Vittecoq, O., Descamps, V., Lo�t, X. L., & Meyer, O. (2003) · Clinical Rheumatology · doi:10.1007/s10067-002-0654-5 · Cited by 189
Niewold, T. B., & Swedler, W. I. (2005) · Clinical Rheumatology · doi:10.1007/s10067-004-1024-2 · Cited by 179
Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody Therapy
Devos, S. A., van den Bossche, N., Vos, M. D., & Naeyaert, J. M. (2003) · Dermatology · doi:10.1159/000069965 · Cited by 147
Naisbitt, D. J., Gordon, S. F., Pirmohamed, M., & Park, B. (2000) · Drug Safety · doi:10.2165/00002018-200023060-00002 · Cited by 146
Adverse reactions to TNF-α inhibitors in rheumatoid arthritis
Day, R. O. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07718-8 · Cited by 131
Allez, M. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)95055-5 · Cited by 125
Platelet Activation and the CD40/CD40 Ligand Pathway: Mechanisms and Implications for Human Disease
Fiocchi, C., & Danese, S. (2005) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v25.i2.20 · Cited by 114
T Regulatory Cells in Allergy and Health: A Question of Allergen Specificity and Balance
Taylor, A., Verhagen, J., Akdiş, C. A., & Akdiş, M. (2004) · International Archives of Allergy and Immunology · doi:10.1159/000080523 · Cited by 94
Managing Immunogenic Responses to Infliximab
Han, P. D., & Cohen, R. D. (2004) · Drugs · doi:10.2165/00003495-200464160-00004 · Cited by 73
Anaphylactic Shock after Retreatment with OKT3 Monoclonal Antibody
Abramowicz, D., Crusiaux, A., & Goldman, M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271018 · Cited by 71
Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy.
Chan, J. L., Davis-Reed, L., & Kimball, A. B. (2004) · PubMed · Cited by 71
Adverse reactions to biologic agents: Focus on autoimmune disease therapies
Lee, S. H., & Kavanaugh, A. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.03.028 · Cited by 70
Anakinra: A Review of its Use in the Management of Rheumatoid Arthritis
Waugh, J., & Perry, C. M. (2005) · BioDrugs · doi:10.2165/00063030-200519030-00005 · Cited by 69
Seçkin, D., Durusoy, Ç., & Şahin, S. (2004) · Pediatric Dermatology · doi:10.1111/j.0736-8046.2004.21512.x · Cited by 62
Solans, R., Bosch, J., Esteban, I., & Vilardell, M. (2004) · PubMed · Cited by 60
Interferon-Alpha-Associated Sarcoidosis Responsive to Infliximab Therapy
Menon, Y., Cucurull, E., Espinoza, L. R., & Reisin, E. (2004) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200409000-00008 · Cited by 57
Kassiotis, G., & Kollias, G. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13362 · Cited by 42
Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C
Kasahara, A., Hiraide, A., Tomita, N., Iwahashi, H., Imagawa, A., Ohguro, N., Yamamoto, S., Mita, E., & Hayashi, N. (2004) · Journal of Gastroenterology · doi:10.1007/s00535-004-1452-4 · Cited by 35
Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
Bagheri, H., Fouladi, A., Barange, K., Lapeyre‐Mestre, M., Payen, J., Montastruc, J. L., & Vinel, J. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.16.1546.50947 · Cited by 35
Long‐term outcome of interferon‐α‐induced autoimmune thyroid disorders in chronic hepatitis C
Doi, F., Kakizaki, S., Takagi, H., Murakami, M., Sohara, N., Otsuka, T., Abe, T., & Mori, M. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01089.x · Cited by 34
Immunologic monitoring during OKT3 therapy
Chatenoud, L. (1993) · Clinical Transplantation · doi:10.1111/j.1399-0012.1993.tb01128.x · Cited by 25
Epidemiology of allergic drug reactions.
Hoigné, R., Schlumberger, H. P., VERVLOET, D., & Zoppi, M. (1993) · PubMed · Cited by 25
Wellington, K., & Perry, C. M. (2005) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200506020-00006 · Cited by 20
Arimura, K., Arima, N., Ohtsubo, H., Matsushita, K., Kukita, T., Ayukawa, T., Kuroki, T., & Tei, C. (2004) · Acta Haematologica · doi:10.1159/000081276 · Cited by 14
Cited by
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 957
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
Krishna, M., & Nadler, S. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00021 · Cited by 389
Metadata
- Authors
- Pichler, W. J.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2006-06
- Volume
- 61
- Issue
- 8
- Pages
- 912-920
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2017200913
- Cited by
- 283
- References
- 40
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.